Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Queensland Health
Moodys
Dow
Citi
Chubb
Johnson and Johnson
Cantor Fitzgerald
AstraZeneca
Cerilliant

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022239

« Back to Dashboard

NDA 022239 describes SUMAVEL DOSEPRO, which is a drug marketed by Endo Ventures Ltd and is included in one NDA. It is available from two suppliers. There are twelve patents protecting this drug. Additional details are available on the SUMAVEL DOSEPRO profile page.

The generic ingredient in SUMAVEL DOSEPRO is sumatriptan succinate. There are twenty-three drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
Summary for 022239
Tradename:SUMAVEL DOSEPRO
Applicant:Endo Ventures Ltd
Ingredient:sumatriptan succinate
Patents:12
Formulation / Manufacturing:see details
Pharmacology for NDA: 022239
Suppliers and Packaging for NDA: 022239
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239 NDA Zogenix, Inc. 43376-104 43376-104-06 6 SYRINGE, GLASS in 1 CARTON (43376-104-06) > .5 mL in 1 SYRINGE, GLASS
SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239 NDA Zogenix, Inc. 43376-104 43376-104-54 4 SYRINGE, GLASS in 1 CARTON (43376-104-54) > .5 mL in 1 SYRINGE, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrengthEQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)
Approval Date:Jul 15, 2009TE:BXRLD:Yes
Patent:➤ SubscribePatent Expiration:Mar 21, 2017Product Flag?YSubstance Flag?Delist Request?
Patent:➤ SubscribePatent Expiration:Dec 9, 2016Product Flag?YSubstance Flag?Delist Request?
Patent:➤ SubscribePatent Expiration:Mar 27, 2017Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 022239

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Subscribe ➤ Subscribe
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Subscribe ➤ Subscribe
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Subscribe ➤ Subscribe
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Subscribe ➤ Subscribe
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Subscribe ➤ Subscribe
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Subscribe ➤ Subscribe
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Colorcon
Cerilliant
Dow
Citi
Mallinckrodt
US Army
Covington
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot